Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Firibastat - Quantum Genomics

Drug Profile

Firibastat - Quantum Genomics

Alternative Names: Amino butane sulfonate disulfure; QGC 001; QGC-011; RB 150

Latest Information Update: 02 Jan 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator CNRS; INSERM; University Paris Descartes
  • Developer Quantum Genomics
  • Class Amines; Aminopeptidases; Antihypertensives; Cardiovascular therapies; Disulfides; Metalloexopeptidases; Sulfonic acids
  • Mechanism of Action Glutamyl aminopeptidase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Chronic heart failure; Hypertension; Left ventricular dysfunction

Most Recent Events

  • 03 Oct 2019 Quantum Genomics plans a pivotal phase III trial for Hypertension in USA (PO, Capsule) by the end of 2019
  • 11 Sep 2019 Quantum Genomics plans a clinical trial for Renal failure in France and Hungary in September 2019
  • 03 Sep 2019 Quantum Genomics plans a phase-III safety trial for resistant Hypertension in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top